Evaluation of disease severity and treatment responses in patients with enthesitis-related arthritis
Authors' conclusion
Although most patients improved, especially with biologics, axial involvement, early diagnosis, and comorbidities were linked to greater disease burden and need for intensive therapy.
Study context
- Population
- Pediatric patients with enthesitis-related arthritis (ERA) diagnosed between January 2015 and October 2023
- Participants
- 133 patients
- Exposure
- Treatment responses to methotrexate, sulfasalazine and biologics; disease activity indices JADAS, BASDAI and JSpADA
- Outcome
- Treatment response by JSpADA and BASDAI
Methodological detailsregional cohort
- Regional cohort
Main finding
As reported in the abstract
Treatment response (JSpADA; BASDAI)
| Outcome | Methotrexate | Sulfasalazine |
|---|---|---|
| Response by JSpADA | 41.1% | 47.2% |
| Response by BASDAI | 49.4% | 58.3% |
Observational data: associations, not effects.
Further findings
Anti-TNF therapy use
- Received anti-TNF therapy
- 60.9%
- Axial involvement, absence of peripheral arthritis, MRI-detected osteitis and comorbidities predicted anti-TNF use
Disease activity indices
- BASDAI and JSpADA showed better correlation and responsiveness than JADAS
Cohort characteristics
- Male
- 74%
- Median symptom onset age
- 12.2 years
- HLA-B27 positivity
- 53.3%
- Axial involvement
- 74.4%
- Methotrexate use (most frequent csDMARD)
- 71%
- HLA-B27 positive patients had higher ESR and CRP and used systemic steroids more often
Original publication
Evaluation of disease severity and treatment responses in patients with enthesitis-related arthritis. Semin Arthritis Rheum. Published 4 March 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →